## Pharmacy Pre-Authorization Criteria

| Drug | Topical Antifungal Agents  
Jublia (efinaconazole)  
Kerydin (tavarborole) |
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Policy #</td>
<td>13118</td>
</tr>
</tbody>
</table>
| Indications | CNL8 (ciclopirox) external Kit, as a component of a comprehensive management program, is indicated as topical treatment in immunocompetent patients with mild to moderate onychomycosis of fingernails and toenails without lunula involvement, due to *Trichophyton rubrum*.  
Jublia is an azole antifungal indicated for the topical treatment of onychomycosis of the toenails due to Trichophyton rubrum and Trichophyton mentagrophytes.  
Kerydin topical solution, 5% is an oxaborole antifungal also indicated for the treatment of onychomycosis of the toenails due to *Trichophyton rubrum* or *Trichophyton mentagrophytes*. |
| Criteria | ConnectiCare considers CNL8, Jublia and Kerydin medically necessary for patients who meet all of the following criteria:  
- The medication must be prescribed by a Dermatologist or Podiatrist  
- Patient must be 18 years of age or older  
- Patient has a diagnosis of onychomycosis of the toenails  
- Patient has had a treatment failure of, or intolerance to, a 3-month course of treatment with oral Lamisil (terbinafine)  
- Patient has had a treatment failure of, or intolerance to, Penlac (ciclopirox)  
Physician documented contraindications to terbinafine include:  
- Abnormal liver function tests  
- Creatinine clearance ≤ 50 ml/min  
- History of hepatitis or another active liver disease |
| Limitations | If the above criteria have been met, approval for any of these medications will be granted for a one-time authorization of 48 weeks. |
| Drug | Topical Antifungal Agents  
#13118 |
# Pharmacy Pre-Authorization Criteria

## References

1. Jublia package insert, Bridgewater, NJ, Valeant Pharmaceuticals
2. Kerydin package insert, Palo Alto, CA, Anacor Pharmaceuticals

## P&T Review History

6/08, 9/09, 9/10, 12/11, 10/12, 10/13, 10/14, 11/15, 8/16, 8/17, 7/18

## Revision Record

9/15, 8/16, 8/17, 7/18